Compare SLDP & ATYR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLDP | ATYR |
|---|---|---|
| Founded | 2011 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Electrical Products | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 876.8M | 79.2M |
| IPO Year | N/A | 2015 |
| Metric | SLDP | ATYR |
|---|---|---|
| Price | $4.49 | $0.74 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 6 |
| Target Price | $7.00 | ★ $8.75 |
| AVG Volume (30 Days) | ★ 6.4M | 2.0M |
| Earning Date | 11-04-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $19,802,000.00 | $190,000.00 |
| Revenue This Year | $27.38 | N/A |
| Revenue Next Year | $36.18 | $18,728.88 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.85 | N/A |
| 52 Week Low | $0.68 | $0.64 |
| 52 Week High | $8.86 | $7.29 |
| Indicator | SLDP | ATYR |
|---|---|---|
| Relative Strength Index (RSI) | 40.45 | 42.35 |
| Support Level | $4.30 | $0.69 |
| Resistance Level | $4.77 | $0.76 |
| Average True Range (ATR) | 0.32 | 0.04 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 16.67 | 29.49 |
Solid Power Inc is engaged in solid-state battery technology and manufacturing processes. Its core technology is a sulfide-based solid electrolyte material, which replaces the liquid or gel electrolyte used in traditional lithium-ion battery cells. Its commercialization plan is to manufacture and sell electrolytes to Tier 1 battery manufacturers and automotive original equipment manufacturers (OEMs) that choose to produce its battery cells.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can cause to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.